Senolytic agents are drugs that selectively eliminate senescent cells, which accumulate with age and contribute to chronic inflammation and tissue dysfunction in neurodegenerative diseases.
This page covers senescence biology, the rationale for senolytic therapy in neurodegeneration, current drug candidates, and clinical development status.
Cellular senescence is a state of irreversible cell cycle arrest characterized by the secretion of pro-inflammatory factors (senescence-associated secretory phenotype, SASP). Senescent cells accumulate in the aging brain and may contribute to neurodegeneration.
Removing senescent cells or suppressing their SASP may reduce neuroinflammation and protect neuronal function.
The field of senolytics emerged from studies showing that clearing senescent cells in aged mice improved healthspan and delayed age-related disorders.
Key senolytic agents include dasatinib plus quercetin (D+Q), fisetin, and navitoclax. Preclinical studies in animal models of Alzheimer's and Parkinson's diseases show promise, and clinical trials are underway to evaluate senolytics in age-related neurodegenerative conditions.
Senolytic agents are drugs that selectively eliminate senescent cells, which are cells that have stopped dividing and secrete pro-inflammatory factors known as the senescence-associated secretory phenotype (SASP). In the aging brain and in neurodegenerative diseases, accumulation of senescent cells contributes to chronic neuroinflammation and neuronal dysfunction. Senolytic therapy represents an emerging therapeutic strategy to clear these harmful cells and potentially slow or reverse neurodegeneration.
Senescent cells are cells that have entered a state of irreversible cell cycle arrest:
- Characteristics: Enlarged cell size, flattened morphology, SA-β-gal positivity
- Secretory phenotype: SASP (Senescence-Associated Secretory Phenotype)
- Growth arrest: p53/p21 and p16/Rb pathways
Senescent cells secrete a variety of pro-inflammatory factors:
- Cytokines: IL-1β, IL-6, IL-8, TNF-α
- Chemokines: CCL2, CXCL8
- Growth factors: VEGF, PDGF
- Proteases: MMP-1, MMP-3
- Extracellular matrix components: Fibronectin
Senescent cells contribute to neurodegeneration through:
- Chronic neuroinflammation: SASP factors drive microglial activation
- Neuronal dysfunction: Paracrine effects on nearby neurons
- Stem cell impairment: Reduced neural progenitor function
- Blood-brain barrier disruption: Endothelial cell senescence
- Accumulation with age: Progressive increase in brain
¶ Dasatinib and Quercetin
Dasatinib is a tyrosine kinase inhibitor:
- Original indication: Chronic myeloid leukemia (Creas)
- Targets: BCR-ABL, Src family kinases
- Senolytic mechanism: Inhibits anti-apoptotic pathways (p53, Bcl-2)
- Properties: Relatively short half-life, good tissue penetration
Quercetin is a flavonoid with multiple biological activities:
- Natural source: Fruits, vegetables, tea
- Mechanisms: Antioxidant, anti-inflammatory, senolytic
- Targets: Bcl-2 family proteins, PI3K/Akt
- Properties: Longer half-life than dasatinib
The D+Q combination is synergistic:
- Different mechanisms: Complementary anti-survival pathways
- Broad efficacy: Targets multiple cell types
- Reduced toxicity: Lower doses of each compound
- Sequential dosing: Optimizes senolytic effect
Senescent cells rely on anti-apoptotic pathways for survival:
- Bcl-2 family: Bcl-2, Bcl-xL, Mcl-1
- p53 pathway: Pro-survival signaling
- PI3K/Akt: Cell survival pathway
D+Q inhibits these pathways:
- Dasatinib: Src kinase inhibition affects Bcl-2 family
- Quercetin: Direct inhibition of Bcl-2, Mcl-1
- Combined effect: Overwhelms anti-apoptotic defenses
The combination is relatively selective for senescent cells because:
- Dependency: Senescent cells are more dependent on anti-apoptotic pathways
- Normal cells: Have redundant survival mechanisms
- Therapeutic window: Doses used are preferentially toxic to senescent cells
Senolytic treatment is followed by:
- Immune cell recruitment: NK cells, macrophages
- Phagocytosis: Clearance of dead senescent cells
- Tissue remodeling: Replacement with healthy cells
In AD models:
- Reduced senescent cell burden: Decreased SA-β-gal+ cells
- Improved cognitive function: Better memory performance
- Reduced neuroinflammation: Lowered IL-6, TNF-α
- Decreased amyloid plaques: Modest reduction
- Enhanced neurogenesis: Improved stem cell function
In PD models:
- Protected dopaminergic neurons: Reduced cell loss
- Improved motor function: Better behavioral outcomes
- Reduced α-synuclein pathology: Decreased aggregation
- Lowered neuroinflammation: Reduced microglial activation
Benefits observed in:
- ALS: Delayed disease progression
- Multiple sclerosis: Reduced demyelination
- Stroke: Smaller infarct, improved recovery
- Traumatic brain injury: Reduced secondary damage
Human studies have established:
- Generally well-tolerated: Main side effects are mild
- Dosing regimens: Various protocols tested
- No serious adverse events: In published trials
- Short-term use: Typically intermittent dosing
| Trial |
Condition |
Regimen |
Duration |
Key Findings |
| NCT02874989 |
Idiopathic pulmonary fibrosis |
D+Q |
3 weeks |
Reduced senescent cells, improved function |
| NCT03430037 |
Alzheimer's disease |
D+Q |
12 weeks |
Ongoing, biomarkers assessed |
| NCT04063124 |
Parkinson's disease |
D+Q |
6 months |
Motor function outcomes |
Trials have measured:
- Senescent cell markers: p16, SA-β-gal, SASP factors
- Inflammatory markers: Cytokines in blood and CSF
- Cognitive function: Standard neuropsychological testing
- Brain imaging: MRI, PET for pathology
A flavonoid with senolytic activity:
- Natural source: Strawberries, apples
- Mechanism: Bcl-2 family inhibition
- Advantages: Good safety profile, oral bioavailability
- Status: Preclinical and early clinical testing
ABT-263, a Bcl-2 family inhibitor:
- Targets: Bcl-2, Bcl-xL, Bcl-w
- Challenge: Thrombocytopenia as side effect
- Status: Preclinical and early clinical testing
| Agent |
Mechanism |
Advantages |
Limitations |
| D+Q |
Broad targeting |
Well-studied, synergistic |
Variable response |
| Fisetin |
Antioxidant, senolytic |
Good safety, natural |
Less potent |
| Navitoclax |
Bcl-2 family |
Potent |
Hematologic toxicity |
| ABT-115 |
Bcl-2 selective |
Targeted |
Early development |
Rationale for AD:
- Senescent glial cells accumulate in AD brain
- SASP drives chronic neuroinflammation
- Neuronal senescence impairs function
- Clearing senescent cells may reduce pathology
Rationale for PD:
- Dopaminergic neurons show senescence markers
- Glial senescence contributes to inflammation
- Age is major risk factor
- Senolytic approach addresses aging component
Potential in:
- Age-related cognitive decline: General brain aging
- Vascular dementia: Vascular cell senescence
- Traumatic brain injury: Post-injury senescence
Senolytics may be combined with:
- Anti-inflammatory agents: Enhanced neuroinflammation reduction
- NAD+ boosters: Combined cellular rejuvenation
- Senostatics: Agents that suppress SASP
- Exercise: Synergistic effects on cellular health
¶ Challenges and Considerations
¶ Dosing and Scheduling
Questions remain about:
- Intermittent vs continuous: Optimal treatment schedules
- Dose optimization: Individualized regimens
- Treatment duration: Long-term effects unknown
- Retreatment: Need for repeated courses
Need for:
- Senescent cell detection: Non-invasive biomarkers
- Target engagement: Confirmation of senolytic effect
- Patient selection: Who benefits most
- Response monitoring: Predictors of benefit
¶ Delivery and Targeting
Challenges include:
- Blood-brain barrier: Achieving CNS exposure
- Cell-type specificity: Targeting relevant senescent cells
- Systemic effects: Peripheral senescent cell clearance
Current status:
- D+Q: Available for research; off-label use
- Clinical trials: Ongoing for multiple conditions
- Prescription: Not yet approved for neurodegeneration
Upcoming trials:
- Larger AD trials: Phase 2/3 planned
- PD trials: Multiple ongoing studies
- Combination trials: With standard therapies
- Biomarker validation: Surrogate endpoints
Future developments:
- Brain-targeted senolytics: Enhanced CNS delivery
- Senostatics: SASP inhibitors without cell death
- Gene therapy: Sustained senolytic expression
- Precision medicine: Biomarker-guided treatment